These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 29768412)

  • 1. Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature.
    Budge PJ; Herbert C; Andersen BJ; Weil GJ
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006454. PubMed ID: 29768412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.
    Edi C; Bjerum CM; Ouattara AF; Chhonker YS; Penali LK; Méité A; Koudou BG; Weil GJ; King CL; Murry DJ
    PLoS Negl Trop Dis; 2019 May; 13(5):e0007325. PubMed ID: 31107869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
    Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
    Thomsen EK; Sanuku N; Baea M; Satofan S; Maki E; Lombore B; Schmidt MS; Siba PM; Weil GJ; Kazura JW; Fleckenstein LL; King CL
    Clin Infect Dis; 2016 Feb; 62(3):334-341. PubMed ID: 26486704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.
    Dubray CL; Sircar AD; Beau de Rochars VM; Bogus J; Direny AN; Ernest JR; Fayette CR; Goss CW; Hast M; O'Brian K; Pavilus GE; Sabin DF; Wiegand RE; Weil GJ; Lemoine JF
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008298. PubMed ID: 32511226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
    Tavul L; Laman M; Howard C; Kotty B; Samuel A; Bjerum C; O'Brian K; Kumai S; Amuga M; Lorry L; Kerry Z; Kualawi M; Karl S; Makita L; John LN; Bieb S; Wangi J; Weil GJ; Goss CW; Tisch DJ; Pomat W; King CL; Robinson LJ
    PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010096. PubMed ID: 35139070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.
    de Souza DK; Ahorlu CS; Adu-Amankwah S; Otchere J; Mensah SK; Larbi IA; Mensah GE; Biritwum NK; Boakye DA
    Trials; 2017 Oct; 18(1):448. PubMed ID: 28969715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.
    King CL; Suamani J; Sanuku N; Cheng YC; Satofan S; Mancuso B; Goss CW; Robinson LJ; Siba PM; Weil GJ; Kazura JW
    N Engl J Med; 2018 Nov; 379(19):1801-1810. PubMed ID: 30403937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018.
    Willis GA; Mayfield HJ; Kearns T; Naseri T; Thomsen R; Gass K; Sheridan S; Graves PM; Lau CL
    PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008854. PubMed ID: 33253148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.
    Weil GJ; Bogus J; Christian M; Dubray C; Djuardi Y; Fischer PU; Goss CW; Hardy M; Jambulingam P; King CL; Kuttiat VS; Krishnamoorthy K; Laman M; Lemoine JF; O'Brian KK; Robinson LJ; Samuela J; Schechtman KB; Sircar A; Srividya A; Steer AC; Supali T; Subramanian S;
    PLoS Med; 2019 Jun; 16(6):e1002839. PubMed ID: 31233507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
    Supali T; Djuardi Y; Christian M; Iskandar E; Alfian R; Maylasari R; Destani Y; Lomiga A; Minggu D; Lew D; Bogus J; Weil GJ; Fischer PU
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009294. PubMed ID: 33780481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co-administration in a field study in an area endemic for lymphatic filariasis in India.
    Kshirsagar NA; Gogtay NJ; Garg BS; Deshmukh PR; Rajgor DD; Kadam VS; Kirodian BG; Ingole NS; Mehendale AM; Fleckenstein L; Karbwang J; Lazdins-Helds JK
    Trans R Soc Trop Med Hyg; 2004 Apr; 98(4):205-17. PubMed ID: 15049459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endpoints for lymphatic filariasis programs.
    Grady CA; de Rochars MB; Direny AN; Orelus JN; Wendt J; Radday J; Mathieu E; Roberts JM; Streit TG; Addiss DG; Lammie PJ
    Emerg Infect Dis; 2007 Apr; 13(4):608-10. PubMed ID: 17553278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis.
    Wkly Epidemiol Rec; 2003 Sep; 78(36):315-7. PubMed ID: 14518107
    [No Abstract]   [Full Text] [Related]  

  • 16. Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India.
    Kuttiatt VS; Somani RK; Swaminathan S; Krishnamoorthy K; Weil GJ; Purushothaman J
    Am J Trop Med Hyg; 2020 Jan; 102(1):96-99. PubMed ID: 31769393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial.
    Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008106. PubMed ID: 32176703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis.
    Andersen BJ; Rosa BA; Kupritz J; Meite A; Serge T; Hertz MI; Curtis K; King CL; Mitreva M; Fischer PU; Weil GJ
    PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007697. PubMed ID: 31557154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India.
    Kshirsagar NA; Gogtay NJ; Garg BS; Deshmukh PR; Rajgor DD; Kadam VS; Thakur PA; Gupta A; Ingole NS; Lazdins-Helds JK
    Parasitol Res; 2017 Oct; 116(10):2683-2694. PubMed ID: 28785847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination.
    Ramaiah KD; Vanamail P; Pani SP; Yuvaraj J; Das PK
    Trop Med Int Health; 2002 Sep; 7(9):767-74. PubMed ID: 12225508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.